





Robert Greene Steme Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Jeffrey T. Helvey Eldora L. Ellison Donald R. Banowit Peter A. Jackman Brian J. Del Buono Mark Fox Evens Vincent L. Capuano Elizabeth J. Haanes Michael D. Specht Kevin W. McCabe Glenn J. Perry Theodore A. Wood Edward W. Yee Grant E. Reed Jason D. Eisenberg Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Helene C. Carlson Cynthia M. Bouchez Limothy A. Doyle Gaby L. Longsworth

June 26, 2008

Lori A. Gordon
Laura A. Vogel
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
W. Blake Coblentz
James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler Jenks
Paul A. Calvo
C. Matthew Rozier*
Randall K. Baldwin

Daniel J. Nevrivy
Lori M. Brandes
Jeffrey K. Mills*
Mita Mukherjee*
Scott M. Woodhouse*
Christian A. Camarce*
Richard D. Coller III*
Keisha Hylton-Rodic
Bonnie Nannenga-Combs
Alyssa K. Sandrowitz*
Jonathan M. Strang*
Ishan P. Weerakoon*

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Peter A. Socarras Danielle L. Letting Steven C. Oppenheimer

Attn: Mail Stop Amendment

Aaron S. Lukas Gauray Asthana Stephanie L. Elmer Robert E. Bakin Salvador M. Bezos Yasser Mourtada

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Wrist
David C. Isaacson

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

WRITER'S DIRECT NUMBER: (202) 772-8856 INTERNET ADDRESS: KMCCABE@SKGF.COM

Art Unit 1644

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re: U.S. Utility Patent Application

Appl. No. 10/782,664; Filed: February 18, 2004

For: SOLUTION-BASED METHODS FOR DETECTING MHC-BINDING PEPTIDES

Inventors: Montero-Julian et al.

Our Ref: 2512.0210001/KWM/C-K (2052-183)

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
- 2. Two (2) pages of Form PTO/SB/08A citing 45 documents (US1-US32 and FP1-FP13);
- 3. A copy of 13 cited documents FP1-FP13;
- 4. Five (5) pages of Form PTO/SB/08B citing 49 documents (NPL1-NPL49);
- 5. A copy of 49 cited documents NPL1-NPL49; and
- 6. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371,2600 f 202.371.2540: www.skgf.com

Commissioner for Patents June 26, 2008 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Kevin W. McCabe Attorney for Applicants

Registration No. 41,182

KWM/C-K/lam Enclosures

839134_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MONTERO-JULIAN et al.

Appl. No.: 10/782,664

Filed: February 18, 2004

SOLUTION-BASED METHODS For: FOR DETECTING MHC-BINDING

PEPTIDES

Confirmation No.: 5199

Art Unit:

1644

Examiner:

DIBRINO, Marianne

Atty. Docket: 2512.0210001/KWM/C-K

(2052-183)

First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. This First Supplemental Information Disclosure Statement is a continuation of the Applicants' Information Disclosure Statement filed on October 17, 2007, in connection with the above-captioned application.

Copies of documents FP1 to FP13 and NPL1 to NPL49 are submitted. However, copies of the U.S. patents and patent application publications, cited on the attached Form PTO/SB/08A as documents US1 to US32, are not submitted in accordance with 37 C.F.R. § 1.98(a)(2).

In accordance with 37 C.F.R. § 1.98(a)(3)A, Applicants' undersigned representative submits the following discussion of the relevance of a non-English language documents, **FP2**, **FP5**, and **FP12**, cited on Form PTO/SB/08A:

Document **FP2**, WO 94/11738 A1, is in the German language. An English language abstract of document FP2 can be found on the face page of the published patent application.

Document **FP5**, WO 97/04085 A1, is in the German language. An English language abstract of document FP5 can be found on the face page of the published patent application.

Document **FP12**, WO 03/040299 A2, is in the French language. An English language abstract of document FP12 can be found on the face page of the published patent application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

MONTERO-JULIAN et al. Appl. No. 10/782,664

- 3 -

not be prior art, and/or to prove that this information may not be enabling for the

teachings purportedly offered.

This statement should not be construed as a representation that a search has been

made, or that information more material to the examination of the present patent

application does not exist. The Examiner is specifically requested not to rely solely on

the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first

Office Action after the filing of a request for continued examination under 37 C.F.R. §

1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the

enclosed IDS Forms, and indicate in the official file wrapper of this patent application

that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee

deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Keviń W. McCabe

Attorney for Applicants Registration No. 41,182

Date: 26 JUN 7008

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 827042_1.DOC